Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

Abstract

BACKGROUND:

We examined risk of newly detected human papillomavirus (HPV) infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment in PATRICIA (Papilloma Trial Against Cancer in Young Adults; NCT00122681).

METHODS:

Using Poisson regression, we compared risk of newly detected infection and cervical abnormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in the control arm (DNA negative at baseline for the corresponding HPV type [HPV-16: n = 8193; HPV-18: n = 8463]).

RESULTS:

High titers of naturally acquired HPV-16 antibodies and/or linear trend for increasing antibody levels were significantly associated with lower risk of incident and persistent infection, atypical squamous cells of undetermined significance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater (CIN1+, CIN2+). For HPV-18, although seropositivity was associated with lower risk of ASCUS+ and CIN1+, no association between naturally acquired antibodies and infection was demonstrated. Naturally acquired HPV-16 antibody levels of 371 (95% confidence interval [CI], 242-794), 204 (95% CI, 129-480), and 480 (95% CI, 250-5756) EU/mL were associated with 90% reduction of incident infection, 6-month persistent infection, and ASCUS+, respectively.

CONCLUSIONS:

Naturally acquired antibodies to HPV-16, and to a lesser extent HPV-18, are associated with some reduced risk of subsequent infection and cervical abnormalities associated with the same HPV type.

• Authors: Xavier Castellsagué, Paulo Naud, Song-Nan Chow, Cosette M Wheeler, Maria Julieta V Germar, Matti Lehtinen, Jorma Paavonen, Unnop Jaisamrarn, Suzanne M Garland, Jorge Salmerón, Dan Apter, Henry Kitchener, Julio C Teixeira, S Rachel Skinner, Genara Limson, Anne Szarewski, Barbara Romanowski, Fred Y Aoki, Tino F Schwarz, Willy A J Poppe, F Xavier Bosch, Newton S de Carvalho, Klaus Peters, Wiebren A A Tjalma, Mahboobeh Safaeian, Alice Raillard, Dominique Descamps, Frank Struyf, Gary Dubin, Dominique Rosillon, Laurence Baril
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 210 Issue 4 Pg. 517-34 (Aug 15 2014) ISSN: 1537-6613 [Electronic] United States
• PMID: 24610876 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

Chemical References

• Antibodies, Viral
• DNA, Viral

Topics

• Adolescent
• Adult
• Antibodies, Viral (immunology)
• DNA, Viral (genetics)
• Double-Blind Method
• Female
• Human papillomavirus 16 (genetics, immunology)
• Human papillomavirus 18 (genetics, immunology)
• Humans
• Papillomaviridae (genetics, immunology)
• Papillomavirus Infections (complications, diagnosis, immunology, virology)
• Risk Factors
• Uterine Cervical Neoplasms (etiology, virology)
• Young Adult
• Uterine Cervical Dysplasia (diagnosis, virology)